149 related articles for article (PubMed ID: 3871218)
1. Treatment of murine lupus with monoclonal anti-T cell antibody.
Wofsy D; Ledbetter JA; Hendler PL; Seaman WE
J Immunol; 1985 Feb; 134(2):852-7. PubMed ID: 3871218
[TBL] [Abstract][Full Text] [Related]
2. Administration of monoclonal anti-T cell antibodies retards murine lupus in BXSB mice.
Wofsy D
J Immunol; 1986 Jun; 136(12):4554-60. PubMed ID: 3086436
[TBL] [Abstract][Full Text] [Related]
3. Treatment of autoimmune MRL/Ipr mice with monoclonal antibody to Thy-1.2: a single injection has sustained effects on lymphoproliferation and renal disease.
Seaman WE; Wofsy D; Greenspan JS; Ledbetter JA
J Immunol; 1983 Apr; 130(4):1713-8. PubMed ID: 6187819
[TBL] [Abstract][Full Text] [Related]
4. Treatment of murine lupus with F(ab')2 fragments of monoclonal antibody to L3T4. Suppression of autoimmunity does not depend on T helper cell depletion.
Carteron NL; Schimenti CL; Wofsy D
J Immunol; 1989 Mar; 142(5):1470-5. PubMed ID: 2521880
[TBL] [Abstract][Full Text] [Related]
5. Polyclonal B cell activation arises from different mechanisms in lupus-prone (NZB x NZW)F1 and MRL/MpJ-lpr/lpr mice.
Merino R; Iwamoto M; Fossati L; Izui S
J Immunol; 1993 Dec; 151(11):6509-16. PubMed ID: 7902378
[TBL] [Abstract][Full Text] [Related]
6. Chronic treatment of C3H-lpr/lpr and C3H-gld/gld mice with anti-CD8 monoclonal antibody prevents the accumulation of double negative T cells but not autoantibody production.
Giese T; Davidson WF
J Immunol; 1994 Feb; 152(4):2000-10. PubMed ID: 8120404
[TBL] [Abstract][Full Text] [Related]
7. Treatment with high doses of anti-IgM prevents, but with lower doses accelerates autoimmune disease in (NZW x BXSB)F1 hybrid mice.
Cerny A; Starobinski M; Hügin AW; Sutter S; Zinkernagel RM; Izui S
J Immunol; 1987 Jun; 138(12):4222-8. PubMed ID: 3495583
[TBL] [Abstract][Full Text] [Related]
8. Treatment of autoimmune MRL/lpr mice with anti-B220 monoclonal antibody reduces the level of anti-DNA antibodies and lymphadenopathies.
Asensi V; Kimeno K; Kawamura I; Sakumoto M; Nomoto K
Immunology; 1989 Oct; 68(2):204-8. PubMed ID: 2478453
[TBL] [Abstract][Full Text] [Related]
9. Reversal of advanced murine lupus in NZB/NZW F1 mice by treatment with monoclonal antibody to L3T4.
Wofsy D; Seaman WE
J Immunol; 1987 May; 138(10):3247-53. PubMed ID: 3106478
[TBL] [Abstract][Full Text] [Related]
10. Prevention of lymphadenopathy in MRL-lpr/lpr mice by blocking peripheral lymph node homing with Mel-14 in vivo.
Mountz JD; Gause WC; Finkelman FD; Steinberg AD
J Immunol; 1988 May; 140(9):2943-9. PubMed ID: 2834447
[TBL] [Abstract][Full Text] [Related]
11. Development of murine lupus in CD4-depleted NZB/NZW mice. Sustained inhibition of residual CD4+ T cells is required to suppress autoimmunity.
Connolly K; Roubinian JR; Wofsy D
J Immunol; 1992 Nov; 149(9):3083-8. PubMed ID: 1357036
[TBL] [Abstract][Full Text] [Related]
12. The effect of thymectomy on lupus-prone mice.
Hang L; Theofilopoulos AN; Balderas RS; Francis SJ; Dixon FJ
J Immunol; 1984 Apr; 132(4):1809-13. PubMed ID: 6142069
[TBL] [Abstract][Full Text] [Related]
13. IL-4Ralpha polymorphism in regulation of IL-4 synthesis by T cells: implication in susceptibility to a subset of murine lupus.
Shiroiwa W; Tsukamoto K; Ohtsuji M; Lin Q; Ida A; Kodera S; Ohtsuji N; Nakamura K; Tsurui H; Kinoshita K; Nishimura H; Shirai T; Hirose S
Int Immunol; 2007 Feb; 19(2):175-83. PubMed ID: 17189592
[TBL] [Abstract][Full Text] [Related]
14. Oncogene expression in autoimmune mice.
Mountz JD; Mushinski JF; Mark GE; Steinberg AD
J Mol Cell Immunol; 1985; 2(3):121-31. PubMed ID: 3916923
[TBL] [Abstract][Full Text] [Related]
15. Anti-CD40 ligand antibody treatment prevents the development of lupus-like nephritis in a subset of New Zealand black x New Zealand white mice. Response correlates with the absence of an anti-antibody response.
Early GS; Zhao W; Burns CM
J Immunol; 1996 Oct; 157(7):3159-64. PubMed ID: 8816428
[TBL] [Abstract][Full Text] [Related]
16. ICAM-1 expression predisposes ocular tissues to immune-based inflammation in dry eye patients and Sjögrens syndrome-like MRL/lpr mice.
Gao J; Morgan G; Tieu D; Schwalb TA; Luo JY; Wheeler LA; Stern ME
Exp Eye Res; 2004 Apr; 78(4):823-35. PubMed ID: 15037117
[TBL] [Abstract][Full Text] [Related]
17. Differential effects of CD4+ T cell depletion on inflammatory central nervous system disease, arthritis and sialadenitis in MRL/lpr mice.
O'Sullivan FX; Vogelweid CM; Besch-Williford CL; Walker SE
J Autoimmun; 1995 Apr; 8(2):163-75. PubMed ID: 7612146
[TBL] [Abstract][Full Text] [Related]
18. [Interleukin 10 in disseminated lupus erythematosus].
Emilie D
J Soc Biol; 2002; 196(1):19-21. PubMed ID: 12134628
[TBL] [Abstract][Full Text] [Related]
19. Studies of T cell deletion and T cell anergy following in vivo administration of SEB to normal and lupus-prone mice.
Scott DE; Kisch WJ; Steinberg AD
J Immunol; 1993 Jan; 150(2):664-72. PubMed ID: 8419493
[TBL] [Abstract][Full Text] [Related]
20. Resistance to tolerance induction is not prerequisite to development of murine SLE.
Izui S; Masuda K
J Immunol; 1984 Dec; 133(6):3010-4. PubMed ID: 6491280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
